Table 3.
Comparison of laboratory profile on day 5.
| Fluvoxamine + SOC (N = 53) |
SOC (N = 50) |
p | |
|---|---|---|---|
| Complete blood count (CBC) | |||
| White Blood Cell count (/μL) | 5520 (IQR 4680–6300) | 5383 (IQR 4500–6600) | 0.75 |
| Lymphocyte count (/μL) | 1862 (IQR 1451–2211) | 1638 (IQR 1210–2005) | 0.03 |
| Lymphocyte count < 1000 (/μL) † | 1(2%) | 4(8%) | 0.20 |
| Hemoglobin (g/dL) | 14 (IQR 13.1–15.0) | 14 (IQR 12.6–15.2) | 0.49 |
| Platelet count (×103/μL) | 214 (IQR 180–267) | 199 (171–276) | 0.63 |
| Biochemistry/Biomarkers | |||
| C-reactive protein (mg/L) | 4 (IQR 2.4–8.9) | 4.6 (IQR 3.1–16) | 0.15 |
| C-reactive protein > 5 mg/L | 22 (42%) | 23 (46%) | 0.69 |
| C-reactive protein > 100 mg/L † | 0 | 3 (20%) | 0.11 |
| Serum ferritin (ng/mL) | 132(IQR 72–199) | 122(IQR 70–188) | 0.9 |
| Serum ferritin > 1000 (ng/mL) † | 0 | 1(2%) | 0.49 |
| Lactate dehydrogenase (LDH) U/L | 165(IQR 140–201) | 166 (IQR 118–193) | 0.43 |
| Creatine phosphokinase (CPK) U/L | 87(66–115) | 77(44–118) | 0.20 |
| Troponin assay > 0.40 ng/mL | 0 | 0 | |
| D-dimer assay > 500 μg/mL | 9 (17%) | 16 (32%) | 0.11 |
† Cut-off designated as laboratory evidence of severe COVID-19 disease by local guidelines [21].